GlassScriptPhysician profile
Leslie E Kathman
NPI 1710657374
$6,550.50
in general payments reported to CMS, 2019-2025
53 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $1,562 · 2023: $1,562 · 2024: $1,742 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.57 |
| Education | $243.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $560.20 | 2021-2025 | Piqray, Kisqali |
| Abbvie INC. | $558.38 | 2022-2025 | |
| Daiichi Sankyo INC. | $523.49 | 2022-2025 | Enhertu, Injectafer |
| Seagen INC. | $399.48 | 2022-2023 | Tukysa, Adcetris, Tivdak |
| E.R. Squibb & Sons, L.L.C. | $374.00 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $373.90 | 2022-2025 | |
| Amgen INC. | $258.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $236.85 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pharmacosmos Therapeutics INC. | $224.05 | 2025 | Monoferric |
| Janssen Biotech, INC. | $222.61 | 2021-2025 | Darzalex, Talvey, Carvykti |
| Sanofi-Aventis U.S. LLC | $199.90 | 2021-2022 | |
| Genentech USA, INC. | $192.49 | 2022-2025 | Venclexta, Itovebi, Columvi |
| Eisai INC. | $192.38 | 2022-2025 | |
| Incyte Corporation | $178.47 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Gilead Sciences, INC. | $154.51 | 2023-2025 | Trodelvy |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $149.43 | 2022-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $136.05 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Adaptive Biotechnologies Corporation | $130.23 | 2022-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $120.09 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $108.55 | 2025 | Enjaymo |
| Mirati Therapeutics, INC. | $94.73 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $92.13 | 2024-2025 | |
| Array Biopharma INC | $78.42 | 2022-2024 | Mektovi, Braftovi, Lorbrena |
| Taiho Oncology, INC. | $76.25 | 2022-2025 | |
| Lilly USA, LLC | $76.15 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Karyopharm Therapeutics INC. | $72.85 | 2022-2024 | Xpovio |
| Genzyme Corporation | $69.69 | 2021-2023 | |
| Celgene Corporation | $65.93 | 2022-2023 | Pomalyst, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $63.06 | 2024-2025 | Libtayo |
| Medtronic, INC. | $58.21 | 2023-2025 | Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| Alexion Pharmaceuticals, INC. | $51.83 | 2024-2025 | Ultomiris |
| Tersera Therapeutics LLC | $43.73 | 2022-2025 | Zoladex |
| Glaxosmithkline, LLC. | $40.55 | 2023-2025 | Blenrep, Ojjaara |
| Stemline Therapeutics INC. | $36.99 | 2024-2025 | Orserdu |
| Astellas Pharma US INC | $32.96 | 2021-2024 | Vyloy |
| Puma Biotechnology, INC. | $29.05 | 2021-2023 | |
| Immunogen, INC. | $23.79 | 2023 | Elahere |
| Ipsen Biopharmaceuticals, INC | $20.41 | 2025 | Onivyde |
| Octapharma USA, INC. | $19.65 | 2024 | Octagam Immune Globulin (Human) |
| Deciphera Pharmaceuticals INC. | $19.47 | 2025 | Romvimza, Qinlock |
| Janssen Pharmaceuticals, INC | $16.88 | 2022 | |
| Syndax Pharmaceuticals, INC. | $16.50 | 2025 | |
| Pharmaessentia USA Corporation | $16.19 | 2023 | Besremi |
| Cti Biopharma Corp. | $16.16 | 2023 | Vonjo |
| Geron Corporation | $15.44 | 2025 | Rytelo |
| Kyowa Kirin, INC. | $15.28 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.23 | 2022 | |
| Spectrum Pharmaceuticals INC. | $14.91 | 2024 | Rolvedon |
| Jazz Pharmaceuticals INC. | $14.36 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.94 | 2022 | |
| Sobi, INC | $12.15 | 2022 | |
| Iovance Biotherapeutics, INC. | $11.25 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Kathman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.